Skip to main content
. 2012 Dec 8;137(2):457–464. doi: 10.1007/s10549-012-2341-9

Table 2.

Disease burden at time of study enrollment

Lapatinib + nab-paclitaxel (n = 60)
Number of organs involved, n (%)
 1 12 (20)
 2 25 (42)
 ≥3 23 (38)
Sites of disease, n (%)
 Lymph nodes 38 (63)
 Lung 32 (53)
 Liver 24 (40)
 Bone 16 (27)
 Breast (de novo Stage IV) 12 (20)